Overview | Zoladex

Prescribing Information ZOLADEX (goserelin) United Kingdom

This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk.

CONFIDENCE THROUGH EVIDENCE

Survival expectations in prostate cancer are higher than ever but so are the demands on your practice to meet these expectations. Healthcare professionals need a treatment designed and tested for the demands of everyday clinical practice.

A device that gives confidence

Ready-to-use, consistent delivery of medicine

Find out more

A proven treatment in prostate cancer.

One treatment. Three key disease settings :

HIGH RISK LOCALISED,
LOCALLY ADVANCED AND
METASTATIC PROSTATE CANCER

Find out more

A treatment which supports your eligible patients

A treatment designed for the demands of your clinical practice.

Find out more

teaser-1
teaser-2
teaser-3

ZOLADEX delivers confidence because:

10 YEARS+ of

survival data^1,2

Clinical data

across 3 key

prostate cancer

settings* from

high-risk localised

to metastatic

disease^1-6

Ready-to-use,

consistent

delivery^5-7

Confidence

established over 

30 years of clinical

practice^5,6

ZOLADEX is classified as a luteinising hormone releasing hormone (LHRH) agonist, which is an agent used for Androgen Deprivation Therapy (ADT).⁸ ADT is the backbone of treatment for prostate cancer,⁸ and it may also be used for the treatment of breast cancer⁹ and endometriosis.¹⁰

Learn more about Zoladex

Key Resources

Administration

Find out more

Patient resources

Find out more

How to purchase

Find out more

ZOLADEX indications for the treatment of prostrate cancer, breast cancer, and other medical conditions

ZOLADEX 3.6 mg implant therapeutic indications

Treatment of prostate cancer in the following settings:
- In the treatment of metastatic prostate cancer where Zoladex has demonstrated comparable survival benefits to surgical castrations
- In the treatment of locally advanced prostate cancer, as an alternative to surgical castration where Zoladex has demonstrated comparable survival benefits to an anti-androgen
- As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Zoladex has demonstrated improved disease-free survival and overall survival
- As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Zoladex has demonstrated improved disease-free survival
- As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression where Zoladex has demonstrated improved disease-free survival
Zoladex 3.6 mg is indicated in the management of oestrogen receptor (ER) positive early and advanced breast cancer in pre and peri menopausal women.
Endometriosis: In the management of endometriosis, Zoladex alleviates symptoms, including pain, and reduces the size and number of endometrial lesions.
Endometrial thinning: Zoladex is indicated for the prethinning of the uterine endometrium prior to endometrial ablation or resection.
Uterine fibroids: In conjunction with iron therapy in the haematological improvement of anaemic patients with fibroids prior to surgery.
Assisted reproduction: Pituitary downregulation in preparation for superovulation.

Zoladex 10.8 mg implant therapeutic indications

Treatment of prostate cancer in the following settings:
- In the treatment of metastatic prostate cancer where Zoladex has demonstrated comparable survival benefits to surgical castrations
- In the treatment of locally advanced prostate cancer, as an alternative to surgical castration where Zoladex has demonstrated comparable survival benefits to an anti-androgen
- As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Zoladex has demonstrated improved disease-free survival and overall survival
- As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Zoladex has demonstrated improved disease-free survival
- As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression where Zoladex has demonstrated improved disease-free survival
Zoladex LA 10.8 mg is indicated in the management of oestrogen-receptor (ER) positive early and advanced breast cancer in pre and peri menopausal women.

Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066–1073.
Carrie C, Magne N, Burban-Provost P, et al. Short term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019; 20(12):1740-1749.
Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991;67:502–508.
Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology. 1995;46:220–226.
ZOLADEX 3.6 mg implant. Summary of Product Characteristics. March 2024. Available at: https://www.medicines.org.uk/emc/product/1543. Accessed on March 2026.
ZOLADEX LA 10.8 mg. Summary of Product Characteristics. April 2023. Available at: https://www.medicines.org.uk/emc/product/1567. Accessed on March 2026.
ZOLADEX HCP. Available at: https://www.zoladexhcp.com/pdf/55673_terzol_ZOL-P-1068_admin_fa2.pdf Accessed on March 2026.
Merseburger AS, Alcaraz A, von Klot CA. Androgen deprivation therapy as backbone therapy in the management of prostate cancer. Onco Targets Ther. 2016;9:7263-7274.
American Cancer Society. Hormone Therapy for Breast Cancer. Available at: https://www.cancer.org/cancer/breast-cancer/treatment/hormone-therapy-for-breast-cancer.html. Accessed March 2026.
Shaw RW. LHRH analogues in the treatment of endometriosis--comparative results with other treatments. Baillieres Clin Obstet Gynaecol. 1988;2(3):659-675.
AstraZeneca. AstraZeneca to invest £120 million in new manufacturing facility to produce Zoladex in Macclesfield. Published 11 November 2013. Available at: https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-manufacturing-facility-macclesfield-zoladex-prostate-cancer-treatment-11112013.html#. Accessed on March 2026.
AstraZeneca. Data on File. Veeva Approval ID: REF-111809.
Gale Academic On file. Double awards for three companies; The Queen's Awards, available at: https://go.gale.com/ps/i.do?id=GALE%7CA116758028&sid=sitemap&v=2.1&it=r&p=AONE&sw= w&userGroupName=anon%7E53d230fa&aty=open-web-entry#:~:text=Pharmaceuticals%20companies%20maintain%20their%20traditional,for%20purifying%20liquids%20and%20gases.. Accessed on March 2026.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

GB-72076 | March 2026

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Cookie Policy

CONFIDENCE THROUGH EVIDENCE

A device that gives confidence

A proven treatment in prostate cancer.

A treatment which supports your eligible patients

ZOLADEX delivers confidence because:

ZOLADEX is classified as a luteinising hormone releasing hormone (LHRH) agonist, which is an agent used for Androgen Deprivation Therapy (ADT).8 ADT is the backbone of treatment for prostate cancer,8 and it may also be used for the treatment of breast cancer9 and endometriosis.10

Key Resources

Indications and Usage

ZOLADEX indications for the treatment of prostrate cancer, breast cancer, and other medical conditions

ZOLADEX 3.6 mg implant therapeutic indications

Zoladex 10.8 mg implant therapeutic indications

References

CONFIDENCE THROUGH EVIDENCE

ZOLADEX is classified as a luteinising hormone releasing hormone (LHRH) agonist, which is an agent used for Androgen Deprivation Therapy (ADT).⁸ ADT is the backbone of treatment for prostate cancer,⁸ and it may also be used for the treatment of breast cancer⁹ and endometriosis.¹⁰